NCT05968326 2026-03-12
IMCODE003
Genentech, Inc.
Phase 2 Recruiting
Clinical Trials
92 trialsNCT05993299 2026-03-11
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT06979596 2026-03-06
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06703346 2026-02-25
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT06005974 2026-02-23
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
Recursion Pharmaceuticals Inc.
Phase 2 Terminated
NCT06593522 2026-02-05
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Amgen
Phase 2 Recruiting
NCT03964727 2026-01-30
TROPiCS-03
Gilead Sciences
Phase 2 Active not recruiting
NCT03697304 2026-01-27
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Boehringer Ingelheim
Phase 2 Completed
NCT05283226 2026-01-23
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NATCO Pharma Ltd.
Phase 2 Recruiting
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT06107413 2025-12-12
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
AbbVie
Phase 2 Active not recruiting
NCT04452955 2025-12-02
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
Intra-IMMUSG Pte Ltd
Phase 2 Active not recruiting
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT04819373 2025-11-12
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
Eikon Therapeutics
Phase 2 Completed
NCT06246110 2025-11-12
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Eikon Therapeutics
Phase 2 Recruiting
NCT04639219 2025-10-16
DPT01
AstraZeneca
Phase 2 Active not recruiting
NCT06175221 2025-09-15
Autologous TLPO Vaccine Basket
Elios Therapeutics, LLC
Phase 2 Terminated
NCT05374915 2025-08-28
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
Kintara Therapeutics, Inc.
Phase 2 Active not recruiting
NCT06010342 2025-07-22
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
Teligene US
Phase 2 Recruiting
NCT06926673 2025-07-03
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
GlaxoSmithKline
Phase 2 Completed
NCT06790303 2025-06-04
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
GlaxoSmithKline
Phase 2 Terminated
NCT06942767 2025-04-27
Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT05673811 2025-04-16
VIRAGE
Theriva Biologics SL
Phase 2 Completed
NCT04976634 2025-04-06
MK-6482-016
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT04014075 2025-04-03
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
Daiichi Sankyo
Phase 2 Completed
NCT05126433 2025-02-28
JAZZ EMERGE201
Jazz Pharmaceuticals
Phase 2 Terminated
NCT00748709 2025-02-11
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
Boehringer Ingelheim
Phase 2 Terminated
NCT04812535 2025-02-11
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
InflaRx GmbH
Phase 2 Terminated
NCT04050436 2025-01-27
CERPASS
Replimune Inc.
Phase 2 Active not recruiting
NCT05097599 2025-01-08
StrataPATH
Strata Oncology
Phase 2 Terminated
NCT01650194 2024-12-10
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
Astellas Pharma Inc
Phase 2 Completed
NCT03760081 2024-11-13
A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors
Astellas Pharma Inc
Phase 2 Completed
NCT04713371 2024-05-09
A Phase 2 Trial for Patients With Metastatic Solid Cancer
Rampart Health, L.L.C.
Phase 2 Active not recruiting
NCT04894994 2023-12-05
FLX475 in Combination With Ipilimumab in Advanced Melanoma
RAPT Therapeutics, Inc.
Phase 2 Terminated
NCT03308942 2023-10-16
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
Tesaro, Inc.
Phase 2 Completed
NCT02213133 2023-01-26
STARRS
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT05553808 2023-01-19
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
GlaxoSmithKline
Phase 2 Completed
NCT02915783 2023-01-17
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Eisai Inc.
Phase 2 Completed
NCT03697707 2022-10-10
ADVANCE-II
Mendus
Phase 2 Unknown
NCT02921919 2022-08-24
Open-Label Extension and Safety Study of Talazoparib
Pfizer
Phase 2 Completed
NCT04003623 2022-05-10
Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
Incyte Corporation
Phase 2 Terminated
NCT02832167 2022-05-09
CheckMate 627
Bristol-Myers Squibb
Phase 2 Completed
NCT02366884 2022-04-06
Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)
Dr. Frank Arguello Cancer Clinic
Phase 2 Unknown
NCT04809012 2022-03-25
Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
Sorrento Therapeutics, Inc.
Phase 2 Withdrawn
NCT03271047 2022-01-04
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Pfizer
Phase 2 Completed
NCT03564548 2021-07-28
REBORN
Tetra Bio-Pharma
Phase 2 Unknown
NCT00545129 2021-06-18
A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone
Pfizer
Phase 2 Completed
NCT02458638 2021-06-04
A Study of Atezolizumab in Advanced Solid Tumors
Hoffmann-La Roche
Phase 2 Completed
NCT03543358 2021-01-05
A Long-Term Study of Rovalpituzumab Tesirine
AbbVie
Phase 2 Completed
NCT00309140 2020-06-26
An Open Label Study of Oral Enzastaurin in Participants With Cancer
Eli Lilly and Company
Phase 2 Completed